Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services or Products of Interest *

When do you expect your project to start?

Project Description

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

* Tick to confirm the Research Use Only (RUO) statement.

Dextofisopam

Inquiry

Specification

Cat. No.

SMD149

Related Diseases

Anxiety

Product Name

Dextofisopam

Size

Customizable

Price

Inquiry

Description

Dextofisopam a non-serotonergic agent currently being evaluated for the treatment of irritable bowel syndrome (IBS), is the R-enantiomer of racemic tofisopam, a molecule marketed and used safely outside the United States for over three decades for multiple indications including IBS. Dextofisopam represents a novel, first-in-class opportunity with a positive proof-of-concept study in an arena where there are few compounds with unique approaches or positive efficacy results. By structure, Dextofisopam is a member of the homophthalazine class; Dextofisopam binds to specific receptors in areas of the brain affecting autonomic function, including gastrointestinal (GI) function. Unlike the two 5-HT3 or 5-HT4 mediated IBS therapies currently available, both with significant safety concerns, Dextofisopam novel non-serotonergic activity offers a unique and innovative approach to IBS treatment. Recent studies have indicated that dextofisopam binds to a novel binding site within the central nervous system that may be responsible for mediating its actions. This receptor has been characterized as the 2,3-benzodiazepine receptor, which is distinct from the classical 1,4 or 1,5-benzodiazepine receptor. Dextofisopam has no significant binding at other receptors or ion channels

CAS Number

82059-50-5

Chemical Formula

C22H26N2O4

Exact Mass

382.1893

Molecular Weight

382.46

Elemental Analysis

C, 69.09; H, 6.85; N, 7.32; O, 16.73

Synonym

Dextofisopam; R-Tofisopam; Tofisopam

IUPAC/Chemical Name

5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5R)-

InChi Key

RUJBDQSFYCKFAA-HNNXBMFYSA-N

InChi Code

InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3/t15-/m0/s1

SMILES Code

CC1=NN=C(C2=CC=C(OC)C(OC)=C2)C3=CC(OC)=C(OC)C=C3[C@H]1CC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4℃ for short term (days to weeks), or -20℃ for long term (months).

HS Tariff Code

2934.99.9001

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.